Home›Somatropin

Somatropin

Also known as: Norditropin

Recombinant Human Growth Hormone

Route: Subcutaneous

29 interactions on record

Somatropin has 29 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cortisone Acetate, Insulin Glargine, Prednisone. Patients taking Somatropin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 29
Major: 4
Moderate: 25

Major (4)

Somatropin + Cortisone Acetate— Somatropin inhibits conversion of cortisone acetate to its active metabolite cortisol. Patients may require increased ma…
Somatropin + Insulin Glargine— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
Somatropin + Prednisone— Somatropin inhibits conversion of prednisone to its active metabolite. Patients may require increased maintenance or str…
Somatropin + Steroid Therapy— Somatropin may inhibit 11β-hydroxysteroid dehydrogenase type 1, reducing serum cortisol and unmasking central hypoadrena…

Moderate (25)

Somatropin + Acidifying Agents— Hypoglycemic agents may require dose adjustment when used concomitantly with somatropin.
Somatropin + Corticosteroids— Somatropin may alter clearance of corticosteroids metabolized by CYP450 liver enzymes; careful monitoring is advised.
Somatropin + Cyclosporine— Somatropin may alter clearance of cyclosporine metabolized by CYP450 liver enzymes; careful monitoring is advised.
Somatropin + Cytochrome P450-Metabolized Drugs— Somatropin may alter clearance of CYP450-metabolized compounds including corticosteroids, sex steroids, anticonvulsants,…
Somatropin + Estrogens— Larger doses of somatropin may be required in women using oral estrogen.
Somatropin + Glimepiride— May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
Somatropin + Glipizide— May reduce glucose-lowering effect of glipizide, leading to worsening glycemic control; monitor closely.
Somatropin + Insulin Aspart Injection— May decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.
Somatropin + Insulin Aspart-Szjj— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Somatropin + Insulin Degludec— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Somatropin + Insulin Degludec And Liraglutide— May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.
Somatropin + Insulin Detemir— May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be …
Somatropin + Insulin Glargine And Lixisenatide— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Somatropin + Insulin Glargine-Aglr— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Somatropin + Insulin Glargine-Yfgn— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Somatropin + Insulin Glulisine— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Somatropin + Insulin Human— Insulin dose may require adjustment when used concomitantly with somatropin.
Somatropin + Insulin Icodec-Abae— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
Somatropin + Insulin Lispro— May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.
Somatropin + Insulin Lispro-Aabc— May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Somatropin + Macimorelin Acetate— May blunt growth hormone response to MACRILEN. Discontinue at least one week before administering MACRILEN diagnostic te…
Somatropin + Nateglinide— May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and…
Somatropin + Oral Anticoagulants— Somatropin may alter clearance of anticonvulsants metabolized by CYP450 liver enzymes; careful monitoring is advised.
Somatropin + Other Anticholinergic Agents— NORDITROPIN may decrease insulin sensitivity, requiring adjustment of hypoglycemic agent doses, particularly at higher N…
Somatropin + Topical Steroids— Somatropin may alter clearance of sex steroids metabolized by CYP450 liver enzymes; careful monitoring is advised.

Somatropin + Cortisone Acetate⚠️Major

Somatropin inhibits conversion of cortisone acetate to its active metabolite cortisol. Patients may require increased maintenance or stress doses.

Somatropin + Insulin Glargine⚠️Major

May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

Somatropin + Prednisone⚠️Major

Somatropin inhibits conversion of prednisone to its active metabolite. Patients may require increased maintenance or stress doses.

Somatropin + Steroid Therapy⚠️Major

Somatropin may inhibit 11β-hydroxysteroid dehydrogenase type 1, reducing serum cortisol and unmasking central hypoadrenalism. Patients on glucocorticoid replacement may require dose increases.

Somatropin + Acidifying Agents🟡Moderate

Hypoglycemic agents may require dose adjustment when used concomitantly with somatropin.

Somatropin + Corticosteroids🟡Moderate

Somatropin may alter clearance of corticosteroids metabolized by CYP450 liver enzymes; careful monitoring is advised.

Somatropin + Cyclosporine🟡Moderate

Somatropin may alter clearance of cyclosporine metabolized by CYP450 liver enzymes; careful monitoring is advised.

Somatropin + Cytochrome P450-Metabolized Drugs🟡Moderate

Somatropin may alter clearance of CYP450-metabolized compounds including corticosteroids, sex steroids, anticonvulsants, and cyclosporine. Careful monitoring recommended.

Somatropin + Estrogens🟡Moderate

Larger doses of somatropin may be required in women using oral estrogen.

Somatropin + Glimepiride🟡Moderate

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Somatropin + Glipizide🟡Moderate

May reduce glucose-lowering effect of glipizide, leading to worsening glycemic control; monitor closely.

Somatropin + Insulin Aspart Injection🟡Moderate

May decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.

Somatropin + Insulin Aspart-Szjj🟡Moderate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Somatropin + Insulin Degludec🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Somatropin + Insulin Degludec And Liraglutide🟡Moderate

May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

Somatropin + Insulin Detemir🟡Moderate

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

Somatropin + Insulin Glargine And Lixisenatide🟡Moderate

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Somatropin + Insulin Glargine-Aglr🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Somatropin + Insulin Glargine-Yfgn🟡Moderate

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Somatropin + Insulin Glulisine🟡Moderate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Somatropin + Insulin Human🟡Moderate

Insulin dose may require adjustment when used concomitantly with somatropin.

Somatropin + Insulin Icodec-Abae🟡Moderate

May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.

Somatropin + Insulin Lispro🟡Moderate

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.

Somatropin + Insulin Lispro-Aabc🟡Moderate

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Somatropin + Macimorelin Acetate🟡Moderate

May blunt growth hormone response to MACRILEN. Discontinue at least one week before administering MACRILEN diagnostic test.

Somatropin + Nateglinide🟡Moderate

May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and increased glucose monitoring may be required.

Somatropin + Oral Anticoagulants🟡Moderate

Somatropin may alter clearance of anticonvulsants metabolized by CYP450 liver enzymes; careful monitoring is advised.

Somatropin + Other Anticholinergic Agents🟡Moderate

NORDITROPIN may decrease insulin sensitivity, requiring adjustment of hypoglycemic agent doses, particularly at higher NORDITROPIN doses.

Somatropin + Topical Steroids🟡Moderate

Somatropin may alter clearance of sex steroids metabolized by CYP450 liver enzymes; careful monitoring is advised.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.